

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/614,370	07/08/2003	Neil David Hammond Raven	1581.0990001/RWE/VSR	1581.0990001/RWE/VSR 7846	
43320	7590 06/27/2006		EXAMINER		
EVAN LAW GROUP LLC 566 WEST ADAMS, SUITE 350			WARE, DEBORAH K		
CHICAGO,	•		ART UNIT PAPER NUMBER		
ŕ			1651		
			DATE MAILED: 06/27/2006	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/614,370 RAVEN ET AL.				
Office Action Summary	Examiner	Art Unit			
	Deborah K. Ware	1651			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence ad	ldress		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO (36(a). In no event, however, may a reply be ti- will apply and will expire SIX (6) MONTHS from (6), cause the application to become ABANDONE	N. mely filed n the mailing date of this c ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 19 J	une 2006.				
· <u> </u>	s action is non-final.				
☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under the	•				
Disposition of Claims					
4) Claim(s) 1-35 is/are pending in the application	L				
4a) Of the above claim(s) <u>12-30</u> is/are withdray					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-11 and 31-35</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
,					
Application Papers					
9) The specification is objected to by the Examine					
10)⊠ The drawing(s) filed on <u>16 December 2003</u> is/a		-	niner.		
Applicant may not request that any objection to the	•	* *			
Replacement drawing sheet(s) including the correc		=			
11) The oath or declaration is objected to by the Ex	xaminer. Note the attached Office	e Action or form P1	ГО-152.		
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreigna) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a	ı)-(d) or (f).			
1. ☐ Certified copies of the priority document	s have been received.				
2. Certified copies of the priority document	ts have been received in Applicat	ion No			
3. Copies of the certified copies of the prio	rity documents have been receiv	ed in this National	Stage		
application from the International Burea	u (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list	of the certified copies not receive	ed.			
Attachment(s)	_				
Notice of References Cited (PTO-892)	4) Interview Summary				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 6/19/06. 12/65	Paper No(s)/Mail D 5) Notice of Informal I 6) Other:		O-152)		
• • •					

DETAILED ACTION

Claims 1-35 are pending.

Information Disclosure Statement

The information disclosure statements (IDSs) submitted on July 8, 2003;

December 16, 2003; January 16, 2005; April 25, 2005; and June 19, 2006, were received. The submissions are in compliance with the provisions of 37 CFR 1.97.

Accordingly, the information disclosure statement is being considered by the examiner.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Preliminary Amendment

The Preliminary Amendment filed December 16, 2003, has been received and entered.

Election/Restrictions

Applicant's election with traverse of Group I, claims 1-11 and 31-35 in the reply filed on April 25, 2006, is acknowledged. The traversal is on the ground(s) that there would be no burden to examine claims 26-27 along with Group I. This is not found persuasive because the method of Group I does not require a buffering agent to be present per se. Further, there is one way distinctness between the product and method wherein the method as stated above does not require a buffering agent. Thus, the restriction is deemed proper.

The requirement is still deemed proper and is therefore made FINAL.

Art Unit: 1651

Claims 12-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention(s), there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on April 25, 2006.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-11 and 31-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shenoy et al (US 5756678), cited on enclosed PTO-892 Form in view of Daniel et al (D1), cited on enclosed copy of PTO-1449 Form filed June 19, 2006.

Application/Control Number: 10/614,370

Art Unit: 1651

Claims are drawn to a method for inactivating a transmissible spongiform encephalopathy (TSE) agent (i.e. prion) comprising exposing the agent to a thermostable proteolytic enzyme.

Shenoy et al teach exposing an infectious prion agent (i.e. TSE) to proteolytic enzyme, note title of invention, column 2, lines 30-35, column 3, lines 50-65, column 9, lines 15-25, and column 15, lines 10-45.

Daniel et al teach thermophilic proteolytic enzymes from Archae bacteria including Bacillus bacteria. Note the entire 27 pages wherein each of temperature and pH are disclosed in Tables 1 and 2.

The claims differ from Shenoy et al in that thermophilic proteolytic enzymes are not disclosed.

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was filed to select for thermophilic proteolytic enzymes for exposing an infectious prion TSE agent disclosed by Shenoy et al to the enzymes disclosed by Daniel et al. Clearly one of skill would have expected successful results and would have been motivated to select for these enzymes because they are more stable. Proteolytic enzymes are well known to deactivate TSE and one of skill would have been motivated to select these enzymes for this purpose. To select for thermostable enzymes having stability at higher temperatures is clearly within the purview of an artisan, and Daniel et al disclose their enzymes work above 40 degrees C and also at 75 degrees C which is within the claimed ranges. To select for alkaline pH is also within the purview of a skilled aritsan. To select for subtilisin derived from Bacillus bacteria or

Art Unit: 1651

MC-A, MC-3 and MC-4 is an obvious modification of the cited prior art . In the absence of convincing evidence to the contrary the claims are prima facie obviouus over the cited prior art.

All claims fail to be patentably distinguishable over the state of the art discussed above and cited on the enclosed PTO-892 and/or PTO-1449. Therefore, the claims are properly rejected.

The remaining references listed on the enclosed PTO-892 and/or PTO-1449 are cited to further show the state of the art.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah K. Ware whose telephone number is 571-272-0924. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/614,370 Page 6

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Deborah K. Ware June 24, 2006